ArticleBMC biology2026
LMO7-mediated ubiquitination of SIRT3 promotes osteoarthritis progression: an investigation using machine learning and molecular dynamics simulations.
Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study aims to inform clinical decision-making by identifying metabolism-related biomarkers involved in the progression of osteoarthritis (OA). Four OA cartilage-related microarray datasets were downloaded from the GEO database. A metabolism-related differentially co-expressed gene signature (MDCGS) associated with OA was then identified through an integrative computational approaches of Weighted Gene Co-expression Network Analysis (WGCNA) and Linear Models for Microarray Data (LIMMA) in combination with machine learning tools. The optimal gene expression and functions were additionally explored in vitro and in vivo. Molecular docking and molecular dynamics simulations (MDs) were conducted to explore the mode of binding with the drug and its role in OA.
resultsAn MDCGS comprising 30 upregulated genes and 29 downregulated genes was identified. The LMO7 gene was determined to exhibit the most prominent importance score within the MDCGS, and subsequent molecular analyses confirmed the ability of LMO7 to ubiquitinate SIRT3, leading to its degradation and subsequent OA progression. Molecular docking and MDs were employed to further investigate the binding mode and stability of LMO7 and its inhibitors. The effectiveness of LM-1685, which had the best binding stability with LMO7, was verified in both in vivo and in vitro experiments.
conclusionsIn summary the series of bioinformatics, machine learning, experimental, molecular docking, and MDs analyses performed in this study led to the identification of LMO7 as a promising target for treating OA progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.